ACM
ELDN icon

Asymmetry Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Asymmetry Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-80,069
Closed -$1.23M – 34
2020
Q4 		$1.23M Buy
80,069
+19,574
+32% +$373K 0.56% 31
2020
Q3 		$1.03M Buy
+60,495
New +$596K 0.66% 31

Other funds holding ELDN

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Asymmetry Capital Management's ELDN Position: Q1 2021 in Review

Asymmetry Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q1 2021, closing a stake of 80,069 shares — an estimated $1.23M sold.

Asymmetry Capital Management first reported a position in ELDN in Q3 2020 and held it in 2 quarters. The position peaked at $1.23M in Q4 2020. 34 funds tracked by Wall St. Rank hold ELDN as of Q1 2021.

  • Asymmetry Capital Management reported no remaining Eledon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 80,069 Eledon Pharmaceuticals shares in Q1 2021, an estimated $1.23M.
  • Asymmetry Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Asymmetry Capital Management's Eledon Pharmaceuticals position peaked at $1.23M in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2021.

Based on Asymmetry Capital Management's 13F filing for Q1 2021, filed 11 May 2021.